Atossa Therapeutics, Inc.
ATOS
$0.83
-$0.08-8.82%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 14.42M | 13.52M | 13.53M | 13.51M | 13.12M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 32.86M | 29.99M | 28.06M | 27.62M | 29.49M |
| Operating Income | -32.86M | -29.99M | -28.06M | -27.62M | -29.49M |
| Income Before Tax | -30.18M | -28.72M | -26.34M | -25.50M | -26.91M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -30.18 | -28.72 | -26.34 | -25.50 | -26.91 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -30.18M | -28.72M | -26.34M | -25.50M | -26.91M |
| EBIT | -32.86M | -29.99M | -28.06M | -27.62M | -29.49M |
| EBITDA | -32.84M | -29.97M | -28.04M | -27.60M | -29.46M |
| EPS Basic | -0.23 | -0.22 | -0.21 | -0.20 | -0.21 |
| Normalized Basic EPS | -0.15 | -0.13 | -0.12 | -0.12 | -0.13 |
| EPS Diluted | -0.23 | -0.22 | -0.21 | -0.20 | -0.21 |
| Normalized Diluted EPS | -0.15 | -0.13 | -0.12 | -0.12 | -0.13 |
| Average Basic Shares Outstanding | 514.12M | 510.72M | 507.29M | 503.44M | 502.12M |
| Average Diluted Shares Outstanding | 514.12M | 510.72M | 507.29M | 503.44M | 502.12M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |